Table 2.
Overall Treatment outcomes.
| Study | DM n(%) |
HIV n(%) |
Smoker n(%) |
ETOH n(%) |
Regimen n(%)* |
Treatment Success n(%) |
Default, Death, Failure (%) |
Data unknown (%)¶ |
|---|---|---|---|---|---|---|---|---|
| Meressa et al.43 | 33 (0.05) |
133 (0.21) |
67 (0.11) |
N/A | S | 481 (0.79) |
95 (0.15) |
0.06 |
| Kempker et al.44 | 16 (0.10) |
6 (0.04) |
N/A | N/A | I | 79 (0.5) |
N/A | N/A |
| Gegia et al.45 | 35 (0.09) |
5 (0.01) |
152 (0.4) |
94 (0.24) |
I | 201 (0.53) |
179 (0.47) |
0.22 |
| Miller et al.46 | N/A | N/A | 343 (0.84) |
253 (0.62) |
N/A | 247 (0.61) |
160 (0.39) |
0.23 |
| Kwak et al.10 | 10 (0.08) |
N/A | 38 (0.31) |
N/A | I | 103 (0.83) |
18 (0.15) |
0.05 |
| Leimane et al.28 | 6 (0.03) |
1 (0.005) |
N/A | 125 (0.61) |
N/A | 135 (0.66) |
69 (0.34) |
0.13 |
| Loveday et al.47 | N/A | 1104 (0.71) |
N/A | N/A | S | 866 (0.56) |
661 (0.43) |
0.23 |
| Seddon et al.11 | N/A | 43 (0.39) |
N/A | N/A | I | 82 (0.74) |
14 (0.13) |
0.14 |
| Duraisamy et al.12 | 60 (0.33) |
1 (0.006) |
25 (0.14) |
16 (0.09) |
S | 112 (0.63) |
66 (0.37) |
0.15 |
| Dheda et al.13 | N/A | 82 (0.47) |
49(0.28) | N/A | S/I | N/A | 62 (0.36) |
N/A |
| Kvasnovsky et al.48 | N/A | 108(0.52) | N/A | N/A | I | N/A | 95 (0.46) |
N/A |
| Shah et al.49 | N/A | 31 (0.37) |
N/A | N/A | N/A | 33 (0.40) |
26 (0.31) |
0.28 |
| Elliott et al.50 | N/A | 93 (0.34) |
N/A | N/A | N/A | 113 (0.42) |
155 (0.57) |
N/A |
| Vashakidze et al.51 | 6 (0.08) |
1 (0.01) |
27 (0.36) |
11 (0.15) |
I | 59 (0.79) |
13 (0.17) |
0.16 |
| Kuaban et al.52 | N/A | 30 (0.2) |
N/A | N/A | S | N/A | N/A | 0.03 |
| Brust et al.53 | N/A | 362 (0.30) |
N/A | N/A | S | 526 (0.44) |
683 (0.56) |
0.21 |
| Van Altena et al.54 | N/A | 14 (0.12) |
N/A | N/A | N/A | 89 (0.79) |
17 (0.15) |
0.13 |
| O’Donnell et al.55 | N/A | 43 (0.72) |
N/A | N/A | N/A | N/A | 31 (0.52) |
0.10 |
| Oladimeji et al.56 | N/A | 28 (0.17) |
N/A | N/A | S | N/A | 24 (0.15) |
N/A |
| Hicks et al.57 | N/A | 64 (0.76) |
N/A | N/A | N/A | 66 (0.79) |
18 (0.21) |
0.06 |
| Ahmad et al.58 | 17 (0.09) |
N/A | 32 (0.16) |
N/A | I | 136 (0.69) |
45 (0.23) |
0.04 |
| Phuong et al.59 | N/A | 53 (0.04) |
N/A | N/A | S | 1008 (0.73) |
196 (0.41) |
0.13 |
| Akshata et al.82 | 8 (0.12) |
3 (0.04) |
N/A | N/A | S | 33 (0.48) |
34 (0.49) |
0.17 |
| Kuksa et al.60 | 3 (0.02) |
16 (0.12) |
N/A | 64 (0.48) |
I | 70 (0.53) |
63 (0.47) |
0.12 |
| Eker et al.61 | N/A | 7 (0.04) |
N/A | N/A | N/A | 109 (0.59) |
17 (0.09) |
0.14 |
| Cox et al.62 | N/A | N/A | 27 (0.31) |
20 (0.23) |
S/I | 54 (0.62) |
33 (0.38) |
0.14 |
| Cegielski et al.14 | 162 (0.13) |
159 (0.13) |
268 (0.22) |
179 (0.14) |
S/I | 722 (0.58) |
483 (0.39) |
0.22 |
| Bendayan et al.63 | 17 (0.13) |
8 (0.06) |
N/A | 34 (0.25) |
I | 70 (0.52) |
62 (0.46) |
0.09 |
| Park et al.15 | N/A | 90 (0.52) |
N/A | N/A | N/A | N/A | 100 (0.58) |
0.18 |
| Farley et al.64 | N/A | 287 (0.38) |
N/A | N/A | S | 348 (0.46) |
409 (0.54) |
0.21 |
| Satti et al.65 | N/A | 94 (0.70) |
N/A | N/A | S | 83 (0.62) |
48 (0.36) |
0.03 |
| Dolgusev et al.66 | N/A | 39 (0.14) |
N/A | N/A | I | 122 (0.45) |
95 (0.35) |
0.21 |
| Khaliaukin et al.67 | N/A | 67 (0.15) |
N/A | N/A | I | 148 (0.33) |
234 (0.53) |
0.13 |
| Kurbatova et al.68 | 68 (0.04) |
27 (0.015) |
272 (0.15) |
489 (0.28) |
I | 1156 (0.65) |
559 (0.32) |
0.17 |
| Oliveira et al.69 | N/A | 108 (0.30) |
N/A | 61 (0.17) |
N/A | 226 (0.62) |
138 (0.38) |
0.07 |
| Franke et al.70 | N/A | N/A | N/A | 28 (0.04) |
I | N/A | 67 (0.10) |
0.10 |
| Lalor et al.71 | N/A | N/A | 76 (0.11) |
90 (0.13) |
I | 438 (0.62) |
272 (0.38) |
0.20 |
| Gandhi et al.72 | N/A | 200 (0.76) |
N/A | N/A | S | N/A | 189 (0.72) |
N/A |
| Tang et al.34 | 80 (0.14) |
N/A | 165 (0.28) |
N/A | I | 240 (0.41) |
334 (0.57) |
0.08 |
| Jeon et al.73 | 26 (0.15) |
N/A | N/A | N/A | I | 28 (0.16) |
114 (0.65) |
0.28 |
| Pazarli et al.74 | 17 (0.17) |
N/A | 61 (0.59) |
N/A | I | 89 (0.86) |
14 (0.14) |
0.02 |
| Jain et al.75 | N/A | N/A | 46 (0.35) |
27 (0.21) |
S | 58 (0.45) |
72 (0.55) |
0.23 |
| Charles et al.76 | N/A | 27 (0.25) |
N/A | N/A | N/A | 43 (0.39) |
15 (0.14) |
0.04 |
| Shin et al.77 | 9 (0.04) |
N/A | 215 (0.88) |
86 (0.35) |
I | 188 (0.77) |
56 (0.23) |
0.11 |
| Marais et al.78 | N/A | 203 (0.58) |
N/A | N/A | S/I | 158 (0.45) |
166 (0.47) |
0.29 |
| Van Der Walt et al.79 | N/A | 393 (0.59) |
N/A | N/A | S | 404 (0.60) |
234 (0.35) |
0.09 |
| Gler et al.80 | 117 (0.27) |
N/A | N/A | N/A | I | 310 (0.71) |
129 (0.29) |
0.18 |
| Chung-Delgado et al.81 | N/A | 10 (0.05) |
N/A | N/A | S/I | 155 (0.77) |
46(0.23) | N/A |
*Default/Loss to follow up/data unavailable/Transfer Out; ¶I = individualized; S = standardized.
§Treatment Completion and/or cure.